Clinical Trial

Albumin and Furosemide for Preventing Ovarian Hyperstimulation Syndrome in ICSI Patients

Study acronym: ALFURO-OHSS
Completed
View on ClinicalTrials.gov →
Summary
This study aims to evaluate whether the combination of Albumin and Furosemide can reduce the risk of Ovarian Hyperstimulation Syndrome in women undergoing intracytoplasmic sperm injection (ICSI) who are at high risk of developing this condition. Ovarian hyperstimulation syndrome is a potential complication of ovarian stimulation during assisted reproductive techniques, which can lead to symptoms such as abdominal swelling, fluid accumulation, and, in severe cases, hospitalization. Preventing this condition is important to improve patient safety and treatment outcomes. In this randomized controlled study, eligible women undergoing ICSI were assigned to receive either the combination of albumin and furosemide or standard care. The study compared the occurrence and severity of OHSS between the two groups. The results of this study may help identify an effective strategy to prevent OHSS and improve the safety of assisted reproductive treatments.
Trial Details
NCT Number NCT07568886
Lead Sponsor Al-Nahrain University
Conditions Ovarian Hyper Stimulation Syndrome (OHSS)
Enrollment 200 participants
Start Date 2019-04-29
Primary Completion 2023-04-27 (estimated)
Study Completion 2024-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-06